Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.

Violette AlloucheryLudivine BeaussireAnne PerdrixDavid SefriouiLaetitia AugustoCécile GuillemetNasrin Sarafan-VasseurFrédéric Di FioreFlorian Clatot

Published in: Breast cancer research : BCR (2018)

Circulating ESR1 mutation detection at the end of AI-based adjuvant treatment is not clinically useful. Circulating ESR1 mutation could be assessed as soon as first relapse to guide interventional studies.

Keyphrases

early stage
estrogen receptor
artificial intelligence
sensitive detection